🟢 Capricor Therapeutics is trading 13.03% up today after the FDA extended deramiocel’s PDUFA target date

Capricor Therapeutics is trading 13.03% up now at $10.58 after the FDA extended deramiocel’s PDUFA target date from August 22 to November 22, 2026.

• The three-month extension follows submission of additional 24-month HOPE-3 data and analyses supporting a refined upper-limb-function indication.
• The move extends a sharp rebound from $6.29 on August 21, following gains of 12.91% on August 26 and 21.91% on August 25.